We only use cookies that are necessary for this site to function to provide you with the best experience. The controller of this site may choose to place supplementary cookies to support additional functionality such as support analytics, and has an obligation to disclose these cookies. Learn more in our Cookie Statement.
Targeted Therapy for Head and Neck Cancer & CAR T-Cell Therapy for Brain Cancer, 01/08/2025
National Cancer Institute sent this bulletin at 01/08/2025 10:50 AM EST
Recent findings from an NCI-supported clinical trial showed that people given the targeted drug cetuximab (Erbitux) had better results than those given the immunotherapy drug durvalumab (Imfinzi). In both cases, people also received radiation.
In a small clinical trial, an experimental CAR T-cell therapy that targets the protein GD2 on cancer cells shrank tumors and improved symptoms in young people with diffuse midline glioma.
NCI Director Dr. Kimryn Rathmell reviews some of the most noteworthy cancer research findings from 2024. Advances included immunotherapy for children with cancer, a potential therapy for cachexia, and studies that provided valuable insights into cancer biology.
Cervical cancer starts in the cervix, the narrow lower end of the uterus. Learn how cervical cancer forms, its causes and risk factors, steps you can take to prevent it, how it is diagnosed and treated, and resources for those coping with a diagnosis.
